By triggering antibody-dependent cellular cytotoxicity (ADCC)-mediated Treg depletion, CTLA-4 antagonists increase the T effector (Teff) cell proliferation and thus an immune response to the tumor [21]. The gene discussed is CTLA4; the disease is neoplasm.